论文部分内容阅读
环吡酮胺是一种新型抗真菌药物,具有抗菌谱广、穿透力强、不良反应小等特点。湖北省医药工业研究所于1984年底开始研制,1985年列为国家医药局局控项目,在有关单位大力协助下完成了全部研究工作。经武汉市第一医院及同济医科大学同济医院临床验证浅部真菌病123例结果表明:痊愈率87.08％;克霉唑对照52例,痊愈率88.5％;二者差异无统计学显著性(P>0.05)。临床观察表明本品止痒效果较佳,平均治愈时间较短。不良反应轻微。为了尽快推向生产,满足广大患者需要。环吡酮胺及其霜剂(软膏)技术鉴定会由国家医药局委托湖北省医药总公司主持,
Ciclopirox olamine is a new antifungal drug with broad antibacterial spectrum, strong penetrating power and little adverse reaction. Hubei Institute of Pharmaceutical Industry started its research and development at the end of 1984, and was listed as a state control project of the State Pharmaceutical Administration in 1985. All the research work was completed with the help of the relevant units. The results of 123 cases of superficial mycosis confirmed by Wuhan First Hospital and Tongji Hospital of Tongji Medical University showed that the cure rate was 87.08%; the clotrimazole control group was 52 cases, the cure rate was 88.5%; the difference was not statistically significant (P > 0.05). Clinical observation shows that this product is better than itching, the average healing time is shorter. Minor adverse reactions. In order to push to production as soon as possible, to meet the needs of the majority of patients. Ciclopirox olamine and cream (ointment) technical appraisal by the State Pharmaceutical Administration commissioned Hubei Province Pharmaceutical Corporation,